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The ICM was isolated using laser microsurgery and plated on γ-irradiated human foreskin ﬁbroblasts. Both the
derivation and cell line propagation were performed in an animal product-free environment and under current
Good Manufacturing Practice (cGMP) standards. Pluripotent state and differentiation potential were conﬁrmed
by in vitro and in vivo assays.
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ﬁbeonsent signed1. Expression of pluripotency ma
rs, visualized with rhodamine-phNov 26, 2008
mbryo thawed Jun 29, 2011
K Stem Cell Bank Deposit
ApprovalReference: SCSC12-37ex Male 46, XY
rade Clinical
isease status Healthy/Unaffectedaryotype (aCGH)
50 kb deletion at 7q22.3
(105,465,968–105,516,305).NP Array
Loss at 8q24.23 (136,718,037–136,837,768)
(Canham et al., 2015)NA ﬁngerprint
Allele sizes (in bp) of 16 microsatellite markers
speciﬁc for chromosomes 13, 18 and 21
(Jacquet et al., 2013)LA typing
HLA-A 02, 24; B 51, 52; Bw 4; C 12, 14; DRB1 11,
15; DRB3 02; DRB5 01; DQB1 03, 06 (Jacquet
et al., 2013; Canham et al., 2015)iability testing Pass
ycoplasma Negative
terility Pass
luripotent markers
(immunostaining)
(Fig. 1)NANOG, OCT4, TRA-1-60, TRA-1-81, AP activityhree germ layer differentiation
in vitro (immunostaining)
(Fig. 2)Endoderm: AFP (α-fetoprotein)
Ectoderm: TUBB3 (tubulin, beta 3 class III)
Mesoderm: ACTA2 (actin, alpha 2, smooth
muscle)hree germ layer differentiation
in vivo (teratomas)
(Fig. 3)Endoderm: AFP, GATA4
Ectoderm: TUBB3, GFAP (glial ﬁbrillary acidic
protein)
Mesoderm: DES (desmin), Alcian Blue and pe-
riodic acid–Schiff (PAS)-stained cartilageargeted differentiation (Fig. 4)
Cardiomyocytes: TNNT2 (cardiac troponin
T) immunostainingibling lines available NoSrkers. Pluripotency is conﬁrmed by immunostaining (Oct
alloidin (red), are present in both feeders and hES cell coWe generated KCL031 clinical grade hESC line following protocols,
established previously (Ilic et al., 2012; Stephenson et al., 2012), and
now adapted to cGMP conditions. The expression of the pluripotency
markers was tested after freeze/thaw cycle (Fig. 1). Differentiation po-
tential into three germ layers was veriﬁed in vitro (Fig. 2) and in vivo
(Fig. 3), aswell as targeted differentiation into cardiacmyocytes (Fig. 4).
Molecular karyotyping using array comparative genomic hybridiza-
tion aCGH identiﬁed deletion at 7q22.3 (105,465,968–105,516,305).
Whole-genome single nucleotide polymorphism (SNP) array analysis
detected loss at 8q24.23 (136,718,037–136,837,768) (Canham et al.,
2015). The gain contains no genes and it has been also reported previ-
ously to occur in healthy individuals from worldwide population
(Macdonald et al., 2014). Estimated frequency in the human population
is 3.85% (Canham et al., 2015).
Donors were tested negative for Human Immunodeﬁciency Virus 1
(HIV1), Hepatitis B (HepB, HCB) and C Virus (HepC, HCV). We did not
retest the line.
We also generated research grade of KCL031 line that is adapted to
feeder-free conditions.
3. Materials and methods
3.1. Consenting process
We distribute Patient Information Sheet (PIS) and consent form to
the in vitro fertilization (IVF) patients if they opted to donate to research
embryos that were stored for 5 or 10 years. They mail signed consent
back to us and that might be months after the PIS and consent were
mailed to them. If in meantime new versions of PIS/consent are imple-
mented, we do not send these to the patients or ask them to re-sign;
thewhole process is donewith the version thatwas given them initially.
The PIS/consent documents (FRO-V.5) were created on Aug. 10, 2007.
HFEA Code of Practice that was in effect at the time of document crea-
tion: Edition 7 — R.1 (http://www.hfea.gov.uk/2999.html). The donor4, Nanog, TRA-1-60, TRA-1-81) and alkaline phosphatase (AP) activity assay. Actin stress
lonies, whereas AP activity (green) is detected only in hES cells. Scale bar, 10 μm.
Fig. 2.Differentiation of three germ layers in vitro is conﬁrmed by detection of markers: smoothmuscle actin (red) formesoderm, β-III tubulin (red) for ectoderm andα-fetoprotein (red)
for endoderm. Nuclei are visualized with Hoechst 33,342 (blue). Scale bar, 50 μm.
197L. Jacquet et al. / Stem Cell Research 16 (2016) 195–198couple signed the consent on Nov. 26, 2008. HFEA Code of Practice that
was in effect at the time of donor signature: Edition 7— R.4. HFEA Code
of Practice Edition 7— R.1 was in effect until Dec. 09, 2007, whereas 7—
R.4 was in effect: Oct. 02, 2008–Sep. 30, 2009.3.2. Embryo culture and micromanipulation
Embryo culture and laser-assisted dissection of inner cell mass
(ICM) were carried out as previously described in details (Ilic et al.,
2012; Stephenson et al., 2012). The cellular area containing the ICM
was then washed and transferred to plates containing mitotically
inactivated human neonatal foreskin ﬁbroblasts (HFF).3.3. Cell culture
ICMplated onmitotically inactivatedHFFwere cultured as described
(Ilic et al., 2012; Stephenson et al., 2012). TE cells were removed me-
chanically from outgrowth (Ilic et al., 2007; Ilic et al., 2010). hESC colo-
nies were expanded and cryopreserved at the third passage.Fig. 3. Differentiation of three germ layers in vivo. Teratomas were encapsulated and did not
speciﬁc stains are brown (immunohistochemistry) or light blue (Alcian blue). Germ layer m
ectoderm, GATA4 and AFP for endoderm. Positive immunostaining for complex IV type II m
desmin). Scale bars are 100 μm.3.4. Viability test
Straws with the earliest frozen passage (p.2–3) are thawed and new
colonies are counted three days later. These colonies are then expanded
up to passage 8, atwhich point cellswere part frozen and part subjected
to standard battery of tests (pluripotency markers, in vitro and in vivo
differentiation capability, genetics, sterility, mycoplasma).
3.5. Pluripotency
Pluripotency in vitro was assessed using two different techniques:
enzymatic activity assay [alkaline phosphatase (AP) assay] and immu-
nostaining as described (Ilic et al., 2012; Stephenson et al., 2012).
3.6. Differentiation
Spontaneous differentiation into three germ layers was assessed
in vitro and in vivo as described (Stephenson et al., 2012; Petrova
et al., 2014). Targeted differentiation in cardiomyocytes followed the
protocols described earlier (Laﬂamme et al., 2007; Jacquet et al., 2015).invade surrounding tissue. Sections are counterstained with hematoxylin and eosin and
arkers: Alcian blue–PAS-stained cartilage and DES for mesoderm, TUBB3 and GFAP for
arker conﬁrms the human origin of the tumor (adjacent section of the one stained for
Fig. 4. TNNT2 (green) immunostaining on day 30 of cardiac differentiation. Nuclei are
visualized with Hoechst 33,342 (blue). Scale bar, 10 μm.
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DNA was extracted from hESC cultures using a Chemagen DNA ex-
traction robot according to the manufacturer's instructions. Ampliﬁca-
tion of polymorphic microsatellite markers was carried out as
described (Ilic et al., 2012). Allele sizes were recorded to give a unique
ﬁngerprint of each cell line.
3.8. Array comparative genomic hybridization (aCGH)
aCGH was performed as described in details (Ilic et al., 2012).
3.9. Whole-genome single nucleotide polymorphism (SNP) array
SNP array was performed as described in details (Canham et al.,
2015).
3.10. HLA typing
HLA-A, -B and -DRB1 typing was performed with a PCR sequence-
speciﬁc oligonucleotide probe (SSOP; Luminex, Austin, TX, USA) hybrid-
ization protocol at the certiﬁed Clinical Transplantation Laboratory,
Guy's and St Thomas' NHS Foundation Trust and Serco Plc. (GSTS) Pa-
thology (Guy's Hospital, London, UK) as described (Jacquet et al.,2013). HLA typing was also performed independently by other group
(Canham et al., 2015).
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